Natera Inc (NTRA) Expected to Post Quarterly Sales of $66.23 Million
Brokerages expect that Natera Inc (NASDAQ:NTRA) will report sales of $66.23 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Natera’s earnings, with the lowest sales estimate coming in at $65.50 million and the highest estimate coming in at $67.25 million. Natera posted sales of $56.66 million in the same quarter last year, which suggests a positive year-over-year growth rate of 16.9%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Natera will report full year sales of $263.08 million for the current year, with estimates ranging from $259.50 million to $266.93 million. For the next year, analysts anticipate that the firm will post sales of $330.80 million, with estimates ranging from $310.00 million to $350.95 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Natera.
Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.55). Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The business had revenue of $63.07 million during the quarter, compared to analysts’ expectations of $61.71 million. During the same period in the previous year, the company earned ($0.55) earnings per share. Natera’s revenue for the quarter was up 20.6% on a year-over-year basis.
Shares of Natera stock traded down $1.76 on Monday, reaching $21.64. The stock had a trading volume of 836,426 shares, compared to its average volume of 413,280. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of -3.32. Natera has a fifty-two week low of $8.60 and a fifty-two week high of $29.62. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -9.02 and a beta of 2.24.
In related news, COO Steven Leonard Chapman sold 35,000 shares of the business’s stock in a transaction on Tuesday, October 2nd. The shares were sold at an average price of $23.76, for a total transaction of $831,600.00. Following the transaction, the chief operating officer now owns 19,022 shares of the company’s stock, valued at $451,962.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew Rabinowitz sold 324,844 shares of the business’s stock in a transaction on Wednesday, September 26th. The stock was sold at an average price of $24.85, for a total transaction of $8,072,373.40. Following the transaction, the chief executive officer now directly owns 982,442 shares in the company, valued at approximately $24,413,683.70. The disclosure for this sale can be found here. Insiders have sold 1,813,321 shares of company stock worth $44,508,270 in the last ninety days. 13.18% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in the stock. Northern Trust Corp increased its position in Natera by 1.5% during the first quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock worth $3,483,000 after acquiring an additional 5,428 shares during the period. Swiss National Bank increased its holdings in Natera by 13.2% in the 1st quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock valued at $444,000 after buying an additional 5,600 shares during the period. State of Wisconsin Investment Board increased its holdings in Natera by 30.4% in the 2nd quarter. State of Wisconsin Investment Board now owns 30,000 shares of the medical research company’s stock valued at $565,000 after buying an additional 7,000 shares during the period. Trexquant Investment LP increased its holdings in Natera by 76.6% in the 2nd quarter. Trexquant Investment LP now owns 22,643 shares of the medical research company’s stock valued at $426,000 after buying an additional 9,820 shares during the period. Finally, State Board of Administration of Florida Retirement System bought a new stake in Natera in the 2nd quarter valued at $200,000. 66.31% of the stock is currently owned by institutional investors and hedge funds.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.